Somewhat Favorable News Coverage Somewhat Unlikely to Impact Laboratory Corp. of America (LH) Stock Price

Headlines about Laboratory Corp. of America (NYSE:LH) have been trending somewhat positive on Tuesday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Laboratory Corp. of America earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 46.8813227172905 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

LH opened at $174.18 on Tuesday. The company has a quick ratio of 1.32, a current ratio of 1.42 and a debt-to-equity ratio of 0.86. Laboratory Corp. of America has a 1 year low of $146.68 and a 1 year high of $190.35. The firm has a market capitalization of $17.80 billion, a P/E ratio of 18.14, a PEG ratio of 1.75 and a beta of 0.98.

Laboratory Corp. of America (NYSE:LH) last posted its earnings results on Wednesday, July 25th. The medical research company reported $2.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.92 by $0.06. Laboratory Corp. of America had a net margin of 11.59% and a return on equity of 16.38%. The firm had revenue of $2.87 billion during the quarter, compared to analysts’ expectations of $2.85 billion. During the same period in the previous year, the business posted $2.47 EPS. The business’s revenue was up 13.4% compared to the same quarter last year. equities research analysts forecast that Laboratory Corp. of America will post 11.54 earnings per share for the current fiscal year.

Several research firms have recently commented on LH. Argus reaffirmed a “buy” rating on shares of Laboratory Corp. of America in a report on Wednesday, August 22nd. Deutsche Bank dropped their price objective on shares of Laboratory Corp. of America from $195.00 to $190.00 and set a “hold” rating on the stock in a report on Monday, August 20th. Mizuho reaffirmed a “hold” rating and issued a $189.00 price objective on shares of Laboratory Corp. of America in a report on Thursday, July 26th. Jefferies Financial Group reaffirmed a “neutral” rating and issued a $180.00 price objective on shares of Laboratory Corp. of America in a report on Thursday, July 26th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Laboratory Corp. of America in a report on Tuesday, July 24th. Six equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Laboratory Corp. of America presently has a consensus rating of “Buy” and an average target price of $196.18.

In other Laboratory Corp. of America news, insider Edward T. Dodson sold 13,000 shares of the company’s stock in a transaction on Wednesday, June 6th. The shares were sold at an average price of $183.35, for a total transaction of $2,383,550.00. Following the completion of the transaction, the insider now directly owns 22,113 shares in the company, valued at $4,054,418.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Glenn A. Eisenberg sold 10,000 shares of the company’s stock in a transaction on Wednesday, May 30th. The stock was sold at an average price of $181.21, for a total transaction of $1,812,100.00. Following the transaction, the chief financial officer now owns 18,843 shares of the company’s stock, valued at $3,414,540.03. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,110 shares of company stock valued at $5,308,925. Company insiders own 0.73% of the company’s stock.

About Laboratory Corp. of America

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens.

Recommended Story: Stock Symbol

Insider Buying and Selling by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply